KalVista Pharmaceuticals logo
KalVista Pharmaceuticals
KALV | NASDAQ
Chart Builder DCF Calculator
$27.00
$0.00 (0.00%)
At close: Jun 10, 2026, 4:00 PM ET

KalVista Pharmaceuticals Company Profile

Company profile explained

Company Profile

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

Key Executives

Name Position
Benjamin L. Palleiko Chief Executive Officer & Director
Bilal Arif Chief Operating Officer
Brian Piekos Chief Financial Officer
Linea Aspesi Chief People Officer
Brian Krex General Counsel
Christopher L. Hamblett Senior Vice President of Corporate Development
Christopher Yea Chief Development Officer
Jarrod Aldom Vice President of Corporate Communications
Paul K. Audhya Chief Medical Officer
Rachel Morten Senior Vice President of Regulatory Affairs & QA
Ryan Baker Head of Investor Relations

Latest SEC Filings

Date Type Title
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 11, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Jun 22, 2026 15-12G Filing
Jun 16, 2026 EFFECT Filing
Jun 11, 2026 S-8 POS Filing
Jun 11, 2026 8-K Current Report
Jun 11, 2026 4 Filing
Jun 11, 2026 4 Filing
View All SEC Filings ➞
KalVista Pharmaceuticals
KalVista Pharmaceuticals logo
Country United States
IPO Date Apr 9, 2015
Industry Biotechnology
Sector Healthcare
Employees 275
CEO Benjamin L. Palleiko

Contact Details

200 Crossing Boulevard Framingham, Massachusetts 01702 United States

Stock Details

Ticker Symbol KALV
Exchange NASDAQ
Fiscal Year May - April
Reporting Currency USD
CIK Code 0001348911
CUSIP Number 483497103
ISIN Number US4834971032
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.